Table 1 Relationships between vimentin and laminin expression and clinicopathological and immunohistochemical characteristics.

	Vimentin‐positive	p Value	Laminin‐positive	p Value
Menopausal status
Premenopausal	17/99 (17.2%)		17/98 (17.3%)
Postmenopausal	34/116 (29.3%)	0.037	22/115 (19.1%)	0.737
Size
p T1	21/114 (18.4%)		18/114 (15.8%)
p T2	23/70 (32.9%)	0.026	17/69 (24.6%)	0.141
Grade
1	4/52 (7.7%)		1/52 (1.9%)
2	9/57 (15.8%)		7/56 (12.5%)
3	34/84 (40.5%)	<0.001	24/83 (28.9%)	<0.001
ER
Positive	11/161 (6.8%)		12/160 (7.5%)
Negative	40/60 (66.7%)	<0.001	27/59 (45.8%)	<0.001
PR
Positive	14/149 (9.4%)		15/147 (10.2%)
Negative	38/74 (51.4%)	<0.001	24/73 (32.9%)	<0.001
p53
Positive	16/60 (26.7%)		17/59 (28.8%)
Negative	35/157 (22.3%)	0.497	22/156 (14.1%)	0.012
HER2
Positive	6/37 (16.2%)		8/35 (22.9%)
Negative	46/187 (24.6%)	0.270	31/187 (16.6%)	0.370
CK5/6
Positive	20/35 (57.1%)		12/35 (34.3%)
Negative	32/186(17.2%)	<0.001	27/184 (14.7%)	0.005
EGFR
Positive	13/21 (61.9%)		7/20 (35.0%)
Negative	38/191 (19.9%)	<0.001	30/191 (15.7%)	0.031
Laminin
Positive	22/39 (56.4%)
Negative	30/181 (16.6%)	<0.001
Basal‐like*
Positive	21/27 (77.8%)		11/26 (42.3%)
Negative	30/194 (15.5%)	<0.001	28/193 (14.5%)	0.001

EGFR, epidermal growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.

*According to Nielsen et al criteria.²⁸